Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icotrokinra - Janssen Biotech

Next Previous
Drug Profile

Icotrokinra - Janssen Biotech

Alternative Names: ICOTYDE; JNJ 77242113; JNJ-2113; PN-21235; PN-235

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protagonist Therapeutics
  • Developer Janssen Biotech
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Butyric acids; Disulfides; Ethanolamines; Indoles; Naphthalenes; Pentanoic acids; Peptides; Phenyl ethers; Pyridines; Sulfhydryl compounds
  • Mechanism of Action Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Plaque psoriasis
  • Phase III Erythrodermic psoriasis; Generalised pustular psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Phase II/III Crohn's disease

Most Recent Events

  • 28 Mar 2026 Efficacy and adverse events data from a phase III ICONIC-LEAD trial in Plaque Psoriasis released by Johnson & Johnson
  • 20 Mar 2026 Protagonist Therapeutics has patent protection for oral peptide IL-23 inhibitors and their use to treat inflammatory bowel diseases in USA, South Korea, Europe, China, Australia and Japan
  • 20 Mar 2026 Protagonist Therapeutics has patents pending for oral peptide IL-23 inhibitors and their use to treat inflammatory bowel diseases in Singapore, Russia, China, Canada and Israel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top